Open Access

Clinical application of plasma mitochondrial DNA content in patients with lung cancer

  • Authors:
    • Jianhua Chen
    • Lemeng Zhang
    • Xun Yu
    • Hui Zhou
    • Yongzhong Luo
    • Wei Wang
    • Lijing Wang
  • View Affiliations

  • Published online on: September 27, 2018     https://doi.org/10.3892/ol.2018.9515
  • Pages: 7074-7081
  • Copyright: © Chen et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Alterations of mitochondrial DNA (mtDNA) have been identified in several types of solid tumor. However, to the best of our knowledge, the clinical significance of plasma mtDNA content in lung cancer remains unknown. Thus, the current study explored the diagnostic and prognostic value of plasma mtDNA quantification in patients with lung cancer. Plasma mtDNA copy numbers of patients with lung cancer (n=128) and healthy individuals (n=107) were quantified by quantitative polymerase chain reaction. Plasma mtDNA copy numbers in patients and healthy controls were 0.89x104 and 1.37x104 copies/µl, respectively (P<0.0001). Furthermore, lower plasma mtDNA content was associated with tumor size, lymph node metastases, distant metastases and serum carcinoembryonic antigen levels (P<0.05), but was not associated with pathological type, age, sex or main driver gene mutation status (P>0.05). Plasma mtDNA facilitated the detection of lung cancer at a threshold of 1.19x104 copies/µl with a sensitivity of 71.1% and specificity of 70.1%, as determined by receiver operating characteristic curve analysis. Advanced stage (III and IV) patients with a lower mtDNA copy number (cutoff: 1.02x104 copies/µl) tended to exhibit poorer prognosis (P<0.05). These results indicated that plasma mtDNA content is a promising and complementary candidate with tissue mtDNA for diagnosis and prognostic prediction for lung cancer.
View Figures
View References

Related Articles

Journal Cover

December-2018
Volume 16 Issue 6

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Chen J, Zhang L, Yu X, Zhou H, Luo Y, Wang W and Wang L: Clinical application of plasma mitochondrial DNA content in patients with lung cancer. Oncol Lett 16: 7074-7081, 2018
APA
Chen, J., Zhang, L., Yu, X., Zhou, H., Luo, Y., Wang, W., & Wang, L. (2018). Clinical application of plasma mitochondrial DNA content in patients with lung cancer. Oncology Letters, 16, 7074-7081. https://doi.org/10.3892/ol.2018.9515
MLA
Chen, J., Zhang, L., Yu, X., Zhou, H., Luo, Y., Wang, W., Wang, L."Clinical application of plasma mitochondrial DNA content in patients with lung cancer". Oncology Letters 16.6 (2018): 7074-7081.
Chicago
Chen, J., Zhang, L., Yu, X., Zhou, H., Luo, Y., Wang, W., Wang, L."Clinical application of plasma mitochondrial DNA content in patients with lung cancer". Oncology Letters 16, no. 6 (2018): 7074-7081. https://doi.org/10.3892/ol.2018.9515